Clik here to view.
Avenge Bio, a cell therapy biotech from Rice, is closed
Cell therapy startup Avenge Bio has shut down, Endpoints News has learned. Chris Garabedian The company ceased all operations and sold its lead asset, Xontogeny CEO Chris Garabedian told Endpoints in...
View ArticleAnother offering for Avidity; Galera shuts down
Plus, news about Kezar Life Sciences, Elicio Therapeutics and Viracta Therapeutics: Avidity seeks $250M in public offering: The money will be used in part to advance its pipeline, Avidity said. Last...
View ArticleClik here to view.
Evotec to cut 400 workers and close sites, citing ‘no new signals of...
Evotec plans to lay off 400 workers and shutter facilities as the German manufacturer and biotech continues to grapple with pharma’s cutback on R&D activities, causing the company to lay off 400...
View ArticleClik here to view.
Verrica’s stock dips despite Phase 2 skin cancer drug clearing more than 50%...
Verrica Pharmaceuticals’ oncolytic peptide that could help eliminate or ease the burden of surgery in basal cell carcinoma has shown signs of efficacy in a mid-phase study. In a secondary endpoint in a...
View ArticleSanofi backs AnaptysBio’s $100M offering, helping catapult the biotech’s stock
AnaptysBio is riding Wall Street momentum, reporting its highest share price in almost five years after a $100 million offering that brought Sanofi aboard. The immunology-focused biotech courted the...
View ArticleClik here to view.
FDA gives accelerated approval to PBC drug at the center of Gilead’s $4.3B...
Six months after buying CymaBay Therapeutics for $4.3 billion, Gilead has secured accelerated approval for seladelpar, the primary biliary cholangitis drug that was at the heart of the takeover. The...
View ArticleInvestment in early-stage health tech startups climbed in the first half of...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Health tech investors have been pouring money into early-stage startups as more mature companies with...
View ArticleClik here to view.
Arrowhead lays out early-stage obesity strategy, including new target on...
Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be “gentler” than currently available GLP-1 products. The target, ALK7, is a receptor on the...
View ArticleClik here to view.
Bluebird's slow sickle cell launch forces rework of loan, putting cash runway...
Bluebird bio reported Wednesday that just four patients have started the process for receiving its sickle cell therapy Lyfgenia, endangering a $50 million loan that the pioneering yet cash-strapped...
View ArticleFDA warning letter targets doctor who worked on a Takeda Phase 3 study
Back in January, Takeda won approval for a new indication for its primary immunodeficiency drug HyQvia, this time as a treatment for a rare autoimmune disorder called chronic inflammatory demyelinating...
View ArticleClik here to view.
Incyte gets another graft-versus-host disease drug approval, this time with...
Incyte and partner Syndax Pharmaceuticals on Tuesday secured regulatory clearance to market a third-line chronic graft-versus-host disease treatment, or cGVHD. The agency greenlit the duo’s axatilimab,...
View ArticleZealand joins next-gen club aiming to ‘accelerate’ obesity drug development
As next-generation contenders in the obesity treatment space communicate plans to speed up their drug programs, Zealand Pharma appears to have gotten the memo. The Danish biotech is raising its...
View ArticleClik here to view.
Biden administration says IRA negotiations will result in $6B in 2026...
The first round of negotiations under the Inflation Reduction Act will save Medicare $6 billion in 2026, the Biden administration announced Thursday. The final prices will be released later today for...
View ArticleIn a reality check for the field, AI underwhelms in Leash Bio's binding...
Artificial intelligence models may be doing a lot more memorizing and a lot less reasoning when it comes to predicting biology, results from a new competition suggest. Shortly after launching in April,...
View ArticleMedicare drug price negotiation list: US reveals prices for first 10 drugs
The government announced final prices on Thursday for the first 10 drugs negotiated by Medicare under the Inflation Reduction Act, following months of back-and-forth between pharma companies and the...
View ArticleNIH says SIGA’s antiviral didn’t improve resolution in mpox lesions in the DRC
A day after the World Health Organization again declared mpox a public health emergency, more bad news came out about the virus. On Thursday, the National Institutes of Health said that SIGA...
View ArticleMerck signs MoU with Indian CDMO; Scorpius delays public offering
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Merck and Indian CDMO Aragen have signed a memorandum of...
View ArticleLyra pauses work on sinusitis drug; Pathos AI licenses a new asset
Plus, news about Convergent Therapeutics, Turnstone Biologics and Sonnet BioTherapeutics: Lyra Therapeutics pauses development of chronic rhinosinusitis drug: The company now plans to focus on two...
View ArticleBavarian Nordic returns to the spotlight as mpox outbreak reaches emergency...
Bavarian Nordic is capable of supplying around three million doses of its mpox vaccine Jynneos this year, the WHO said following its global health emergency declaration. WHO Director-General Tedros...
View ArticleClik here to view.
Lykos cutting most of staff less than a week after FDA rejection
Lykos Therapeutics is cutting 75% of its staff following the FDA’s rejection last week of its MDMA-assisted therapy, the company said Thursday. Rick Doblin Rick Doblin, founder and president of the...
View Article